Device Trial Radar · NCT05422131
Clozapine Therapy Sample Collection - Method Comparison Study
Last checked: Nov 20, 2026Latest source record: May 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
153
Actual
Start
Nov 12, 2022
Primary completion
Jan 25, 2023
Study completion May 16, 2023
Sponsor
- Lead sponsor
- Saladax Biomedical, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Northwell Health; University of Maryland, Baltimore
- First posted
- Jun 16, 2022
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The method comparison study involves capillary fingerstick blood, venous serum, and venous K2EDTA blood sample collection from human subjects receiving clozapine treatment and their clozapine concentration measurement using a validated mass spectrometry method, the automated immunoassay MyCare Psychiatry Clozapine Assay Kit manufactured by SBI, and the point of care MyCare Insite Clozapine Test manufactured by SBI. Clozapine measurements obtained using the MyCare Insite Clozapine Test are intended for investigational purposes only and shall not be used in the management of patients receiving clozapine therapy.
Conditions
- Patients Prescribed Clozapine
Interventions
MyCare Insite Clozapine TestDevice
The MyCare Insite Clozapine Test is a 2 reagent system designed to evaluate the level of antipsychotic drug clozapine in a patients blood using the near patient device the MyCare Insite Analyser.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sample Analysis - Method ComparisionTime frame: October, 2022
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Saladax Biomedical, Inc.
Bethlehem, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.